Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Cross-modulation and molecular interaction at the Cav3.3 protein between the endogenous lipids and the T-type calcium channel antagonist TTA-A2.

Cazade M, Nuss CE, Bidaud I, Renger JJ, Uebele VN, Lory P, Chemin J.

Mol Pharmacol. 2014 Feb;85(2):218-25. doi: 10.1124/mol.113.089581. Epub 2013 Nov 8.

2.

Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine.

Ross HR, Gilmore AJ, Connor M.

Br J Pharmacol. 2009 Mar;156(5):740-50. doi: 10.1111/j.1476-5381.2008.00072.x. Epub 2009 Feb 16.

3.

In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.

Kraus RL, Li Y, Gregan Y, Gotter AL, Uebele VN, Fox SV, Doran SM, Barrow JC, Yang ZQ, Reger TS, Koblan KS, Renger JJ.

J Pharmacol Exp Ther. 2010 Nov;335(2):409-17. doi: 10.1124/jpet.110.171058. Epub 2010 Aug 3.

4.

T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids.

Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinet E, Chemin J.

J Neurosci. 2009 Oct 21;29(42):13106-14. doi: 10.1523/JNEUROSCI.2919-09.2009.

5.

Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT.

Gilmore AJ, Heblinski M, Reynolds A, Kassiou M, Connor M.

Br J Pharmacol. 2012 Nov;167(5):1076-88. doi: 10.1111/j.1476-5381.2012.02047.x.

6.

State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects.

Francois A, Kerckhove N, Meleine M, Alloui A, Barrere C, Gelot A, Uebele VN, Renger JJ, Eschalier A, Ardid D, Bourinet E.

Pain. 2013 Feb;154(2):283-93. doi: 10.1016/j.pain.2012.10.023. Epub 2012 Nov 5.

PMID:
23257507
7.

Modulation of T-type calcium channels by bioactive lipids.

Chemin J, Cazade M, Lory P.

Pflugers Arch. 2014 Apr;466(4):689-700. doi: 10.1007/s00424-014-1467-5. Epub 2014 Feb 16. Review.

PMID:
24531745
8.

Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels.

Chemin J, Nargeot J, Lory P.

J Biol Chem. 2007 Jan 26;282(4):2314-23. Epub 2006 Nov 22.

9.

T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats.

Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, Vardigan JD, Nguyen SJ, Surles NO, Yao L, Barrow JC, Uebele VN, Renger JJ, Clark J, Hutson PH.

Neuropharmacology. 2012 Mar;62(3):1413-21. doi: 10.1016/j.neuropharm.2010.11.015. Epub 2010 Nov 24.

PMID:
21110986
11.

Positive allosteric interaction of structurally diverse T-type calcium channel antagonists.

Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ.

Cell Biochem Biophys. 2009;55(2):81-93. doi: 10.1007/s12013-009-9057-4. Epub 2009 Jul 7.

PMID:
19582593
12.

Inhibition of [3H]batrachotoxinin A-20alpha-benzoate binding to sodium channels and sodium channel function by endocannabinoids.

Duan Y, Zheng J, Nicholson RA.

Neurochem Int. 2008 Feb;52(3):438-46. Epub 2007 Aug 13.

PMID:
17888543
13.

Anandamide and NADA bi-directionally modulate presynaptic Ca2+ levels and transmitter release in the hippocampus.

Köfalvi A, Pereira MF, Rebola N, Rodrigues RJ, Oliveira CR, Cunha RA.

Br J Pharmacol. 2007 Jun;151(4):551-63. Epub 2007 Apr 16.

14.

CaV3.2 T-type Ca2+ channels mediate the augmented calcium influx in carotid body glomus cells by chronic intermittent hypoxia.

Makarenko VV, Ahmmed GU, Peng YJ, Khan SA, Nanduri J, Kumar GK, Fox AP, Prabhakar NR.

J Neurophysiol. 2016 Jan 1;115(1):345-54. doi: 10.1152/jn.00775.2015. Epub 2015 Nov 11.

PMID:
26561606
15.

N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia.

Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, Zipkin RE, Daddario N, Appendino G, Di Marzo V, Walker JM.

J Biol Chem. 2003 Apr 18;278(16):13633-9. Epub 2003 Feb 4.

16.

Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels.

De Petrocellis L, Chu CJ, Moriello AS, Kellner JC, Walker JM, Di Marzo V.

Br J Pharmacol. 2004 Sep;143(2):251-6. Epub 2004 Aug 2.

17.

Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide.

Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P.

EMBO J. 2001 Dec 17;20(24):7033-40.

18.

N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels.

Parmar N, Ho WS.

Br J Pharmacol. 2010 Jun;160(3):594-603. doi: 10.1111/j.1476-5381.2009.00622.x. Epub 2010 Feb 5.

19.

The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes.

Wojtalla A, Herweck F, Granzow M, Klein S, Trebicka J, Huss S, Lerner R, Lutz B, Schildberg FA, Knolle PA, Sauerbruch T, Singer MV, Zimmer A, Siegmund SV.

Am J Physiol Gastrointest Liver Physiol. 2012 Apr 15;302(8):G873-87. doi: 10.1152/ajpgi.00241.2011. Epub 2012 Feb 2.

20.

Pharmacology of recombinant low-voltage activated calcium channels.

Lacinov√° L.

Curr Drug Targets CNS Neurol Disord. 2004 Apr;3(2):105-11. Review.

PMID:
15078185
Items per page

Supplemental Content

Write to the Help Desk